## Core Concept
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist used in the prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). It works by blocking the emetic effects of substance P, which is involved in the vomiting reflex. This mechanism is distinct from other antiemetic classes.

## Why the Correct Answer is Right
Aprepitant's mechanism of action involves the selective binding to the NK1 receptor, preventing substance P from interacting with this receptor, which in turn reduces the likelihood of vomiting. This is a unique approach compared to other antiemetics that target different pathways, such as serotonin (5-HT3) receptors or dopamine receptors.

## Why Each Wrong Option is Incorrect
- **Option A:** Aprepitant is indeed used for the prevention of chemotherapy-induced nausea and vomiting (CINV), making this statement true.
- **Option B:** Aprepitant is also used for the prevention of postoperative nausea and vomiting (PONV), although its use might be less common compared to CINV, this statement can be considered true.
- **Option C:** The drug is known to have a specific and unique mechanism of action through NK1 receptor antagonism, which makes this option likely incorrect based on the context that might imply a different or incorrect mechanism.
- **Option D:** Aprepitant does have a role in combination therapy for enhancing the effectiveness of other antiemetics, making this statement true.

## Clinical Pearl / High-Yield Fact
A key point to remember about aprepitant is its use in combination with other antiemetics (like ondansetron and dexamethasone) for the prevention of acute and delayed CINV. Aprepitant's effectiveness in delayed CINV is particularly noteworthy, as it provides benefits beyond what 5-HT3 antagonists and corticosteroids offer alone.

## Correct Answer: C.